A Dual‐Responsive Morphologically‐Adaptable Nanoplatform for Targeted Delivery of Activatable Photosensitizers in Precision Photodynamic Therapy
Small · 2024
DOI: 10.1002/smll.202309054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Qishu Jiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, China Pharmaceutical University, Nanjing, 210009, China. Hauptthemen laut MEDLINE: Photochemotherapy, Photosensitizing Agents, Nanoparticles. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Photodynamic therapy (PDT) is an effective approach for treating melanoma. However, the photosensitizers employed in PDT can accumulate in healthy tissues, potentially causing harm to normal cells and resulting in side effects such as heightened photosensitivity. To address this, an activatable photosensitizer (PSD) by linking PpIX with a fluorescence quencher using a disulfide bond is designed. PSD responded to endogenous GSH, showing high selectivity for A375 cells. To enhance PSD's bioavailability and anticancer efficacy, an enzyme‐responsive nanoplatform based on a lonidamine‐derived self‐assembling peptide is developed. Initially, PSD and the peptide self‐assembled into nanoparticles, displaying potent tumor targeting of PSD in vivo. Upon cell uptake, these nanoparticles specifically responded to elevated cathepsin B, causing nanoparticle disintegration and releasing PSD and lonidamine prodrug (LND‐1). PSD is selectively activated by GSH for cancer‐specific fluorescence imaging and precision PDT, while LND‐1 targeted mitochondria, forming a fibrous lonidamine depot in situ and intensifying photosensitizer's cytotoxicity through ROS generation, mitochondrial dysfunction, and DNA damage. Notably, intravenous administration of LND‐1‐PEG@PSD with light irradiation significantly suppressed A375‐xenografted mouse tumor growth, with minimal systemic toxicity. Together, the synergy of activatable photosensitizer and enzyme‐responsive nanoplatform elevates PDT precision and diminishes side effects, showcasing significant potential in the realm of cancer nanomedicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, China Pharmaceutical University, Nanjing, 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy and Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing, 211198, China.
- Key Laboratory of Biomedical Functional Materials, China Pharmaceutical University, Nanjing, 210009, China.
- Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Nanjing, 210009, China.
ORCID-Profile: Wenying Zhong
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiao, Q., Zheng, Y., Xie, Q., Luo, X., Zhou, S., Pei, S., Zhang, T., Wu, X., Xu, K., & Zhong, W. (2024). A Dual‐Responsive Morphologically‐Adaptable Nanoplatform for Targeted Delivery of Activatable Photosensitizers in Precision Photodynamic Therapy. Small. https://doi.org/10.1002/smll.202309054
Vancouver
Jiao Q, Zheng Y, Xie Q, Luo X, Zhou S, Pei S, et al. A Dual‐Responsive Morphologically‐Adaptable Nanoplatform for Targeted Delivery of Activatable Photosensitizers in Precision Photodynamic Therapy. Small. 2024. doi:10.1002/smll.202309054
BibTeX
@article{Jiao2024,
author = {Jiao, Qishu and Zheng, Yaxin and Xie, Qinqing and Luo, Xuan and Zhou, Shuyao and Pei, Shicheng and Zhang, Tingting and Wu, Xiaoxing and Xu, Keming and Zhong, Wenying},
title = {A Dual‐Responsive Morphologically‐Adaptable Nanoplatform for Targeted Delivery of Activatable Photosensitizers in Precision Photodynamic Therapy},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202309054}
}
EUVIMED